SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- SpectraScience, Inc. , a San Diego based medical device company, today announced that it has hired several individuals to drive its operational growth as it moves from an R&D focus towards a revenue generating business model in 2008:
Jim Hitchin, SpectraScience’s CEO, stated, “The addition of these senior members to our team is critical in our go-to-market strategy for 2008. We expect to ramp-up operations this year and have recently expanded our facilities to accommodate increased production. With these new team members, we expect to strengthen our business model and drive sales. These new leaders are part of our continuing evolution to become a major player in the burgeoning market for early disease detection and point of care diagnostics.”
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT(TM) Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA clearance for sale in the U.S. and the CE Mark for the European Union, the WavSTAT(TM) system is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA(TM) imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
http://www.spectrascience.com
CONTACT: Jim Hitchin, Chief Executive Officer of SpectraScience, Inc.,
+1-858-847-0200, ext. 201; or investor relations, Todd Pitcher of Hayden
Communications, +1-858-518-1387, for SpectraScience, Inc.
Web site: http://www.spectrascience.com/
